Lipfendra (enlicitide decanoate)
Merck Sharp & Dohme (MRK)
ApprovedJul 15, 2026
Marketer take
An oral PCSK9 inhibitor that brings the injectable class's mechanism to a pill, which pressures Repatha, Praluent and Leqvio and widens the lipid audience from cardiology into primary care.
- Sponsor company
- Merck Sharp & Dohme (MRK)
- Indication
- To reduce low-density lipoprotein cholesterol
- Therapeutic area
- Cardiovascular
- Event
- FDA approval
- Date
- Jul 15, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?